Stock vs Stock Comparison

ResMed Inc. vs Abbott Laboratories

RMD wins the Tale of the Tape 9–0.

RMD$198.99
ABT$100.68

🏆 Tale of the Tape

90
RMDABT
27.2%Profitability (Net Margin)14.7%
19.6xValuation (P/E)27.7x
18.6%Efficiency (ROIC)10.1%
7/9Health (Piotroski F)5/9
10.6Safety (Altman Z)4.9
9.8%Growth (Rev YoY)5.7%
-0.93Risk (Sharpe 1Y)-0.98
0.37xBalance Sheet (D/E)0.64x
5.83%FCF Yield4.18%

Green = winner in each category. Higher is better except P/E (lower = cheaper).

Rolling Correlation

0.366
252-Day Correlation
0.406
126-Day Correlation

Moderately correlated — some diversification benefit from holding both.

Fundamentals

MetricRMDABT
Market Cap$28.9B$175.4B
P/E Ratio19.6x27.7x
Forward P/E16.6x16.6x
P/B4.45x3.35x
Dividend Yield1.18%0.03%
Beta0.780.61

Quantitative Metrics

MetricRMDABT
DCF Fair Value$333.78$67.82
DCF Upside+67.7%-32.6%
Piotroski F7/95/9
Altman Z10.574.89
Beneish M-2.62-2.53
FCF Yield5.83%4.18%
Net Debt/EBITDA-0.3x0.1x
ROIC18.6%10.1%
WACC9.5%8.4%
ROIC – WACC9.1pp1.7pp
Gross Margin59.4%56.4%
Net Margin27.2%14.7%
Rev Growth YoY9.8%5.7%
Sharpe (1Y)-0.93-0.98
Max Drawdown 3Y
FCF Payout Ratio19%56%

RMD Price

Loading chart...

ABT Price

Loading chart...

ETF Exposure

RMD found in:

IHI4.38%
XHE1.61%
VOT0.62%
XLV0.50%
ONEV0.43%
VHT0.42%
ONEY0.34%
VO0.27%
RSP0.17%
SCHG0.14%
ONEO0.13%
VIG0.12%
VUG0.10%
IWD0.08%
VONV0.08%
IVV0.07%
ESGV0.07%
QUS0.07%
SPLG0.06%
ITOT0.06%
SCHX0.06%
SCHB0.06%
SPYG0.05%
SPY0.05%
SPYV0.04%
URTH0.04%
SPTM0.04%
VONE0.04%
VOO0.04%
VTI0.04%
DGRW0.04%
ACWI0.03%
IWF0.03%

ABT found in:

IHI16.93%
XLV2.94%
IYH2.64%
VHT2.33%
XHE1.71%
DGRW1.43%
NOBL1.34%
SDY1.07%
MGV0.75%
VIG0.69%
VFMV0.69%
SCHV0.68%
VYM0.65%
VTV0.59%
IWD0.58%
SPYV0.58%
VONV0.44%
IVV0.41%
QUS0.37%
SPLG0.37%
ESGV0.36%
ITOT0.36%
SCHX0.33%
SCHB0.30%
SPY0.27%
SPTM0.25%
VOO0.24%
URTH0.24%
VONE0.23%
VTI0.22%
ACWI0.16%
RSP0.16%
VT0.13%
ONEO0.05%

More Comparisons

Quant metrics computed from financial statements and 1,200+ trading days. Correlation is Pearson coefficient on daily log returns. Not investment advice.

RMD vs ABT: Head-to-Head Analysis

ResMed Inc. (RMD) and Abbott Laboratories (ABT) represent two companies in the Healthcare sector. In our quantitative Tale of the Tape scoring, RMD leads 9–0 across nine fundamental and risk metrics including profitability, valuation, capital efficiency, and financial health.

In terms of capital efficiency, RMD generates a return on invested capital (ROIC) of 18.6% compared to ABT's 10.1%. This suggests RMD is more effective at deploying capital to generate shareholder returns.

The 252-day rolling correlation between RMD and ABT is 0.366, indicating moderate co-movement, with some diversification value from holding both in a portfolio context.

RMD appears in 33 ETFs tracked by SecuritiesDB, while ABT appears in 34 ETFs. Investors holding broad-market ETFs may already have indirect exposure to both stocks.

Frequently Asked Questions

Which stock is the better investment, RMD or ABT?

Our quantitative analysis compares RMD and ABT across nine fundamental dimensions. RMD wins the Tale of the Tape 9–0. However, stock selection depends on your individual risk tolerance, time horizon, and portfolio context. These metrics are computed from SEC filings and market data — they are not investment recommendations.

Are RMD and ABT correlated?

The 252-day correlation between RMD and ABT is 0.366. They show moderate correlation — partially diversifying.

How is the Tale of the Tape scored?

The Tale of the Tape compares both stocks across nine categories: profitability (net margin), valuation (P/E), efficiency (ROIC), health (Piotroski F-Score), safety (Altman Z-Score), growth (revenue YoY), risk (Sharpe ratio), leverage (debt-to-equity), and cash generation (FCF yield). The stock that wins more categories takes the overall score. Lower P/E and lower debt-to-equity count as wins.